Navigation Links
Aratana Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/13/2013

KANSAS CITY, Kan. and BOSTON, Nov. 13, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX) today announced its third quarter 2013 financial results and recapped its development activities.

"This has been a very productive quarter for Aratana," said Dr. Steven St. Peter, President and CEO of Aratana Therapeutics. "We have continued to move forward in establishing ourselves as the premier pet therapeutics company."

The quarter was highlighted by the signing of two option agreements, and the continued progress of the company's development programs. In mid-October, Aratana acquired Vet Therapeutics, a San Diego-based biologics company whose first products are being developed as treatments for lymphoma in dogs and cats, one of the most prevalent cancers in our pets.

Development Programs and Upcoming Milestones

  • AT-001 Dog: Topline results from dose-ranging field study expected in the second half of November 2013; continue to anticipate U.S. approval in 2016
  • AT-001 Cat: Pursuing a chronic pain claim
  • AT-002 Dog: Agreement on pivotal study design reached with Center for Veterinary Medicine (CVM); pivotal field study effectiveness protocol submitted to CVM for review; expect to initiate pivotal study in late 2013; continue to anticipate U.S. approval in 2016
  • AT-002 Cat: Selected three week treatment term and weight gain and/or control claim for further proof of concept work; final formulation selected; expect results 1H 2014
  • AT-003 Dog: Continued dose-ranging study in laboratory dogs; anticipate discussions with the CVM on development program in late 2013; continue to anticipate U.S. approval in 2016
  • AT-003 Cat: Initiated dose-ranging study in laboratory cats
  • Option Programs: Evaluation
    '/>"/>

  • SOURCE Aratana Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Aratana to Participate in Leerink Swanns November Management Access Days
    2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
    3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
    4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
    5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
    6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
    7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
    8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
    9. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
    10. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
    11. Aratana Therapeutics names Wendy Yarno to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
    (Date:9/17/2014)... -- Women everywhere know how frustrating a vaginal infection ... often also embarrassing and have a way of derailing ... http://ph-defense.com ) is a new, over-the-counter product designed to ... Odor, discharge, and discomfort or itch ... many cases, the cause of such problems can be ...
    (Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... of its public offering of 4,500,000 shares of its common ... $9.25 per share. Aratana has granted the underwriters ... additional 675,000 shares of its common stock. ...
    Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
    ... Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today ... midazolam injection, USP, a general anesthetic.  Sagent expects ... latex-free vials, in 2011.  According to 2010 IMS ... approximated $52 million.   "Approval of ...
    ... Genous Stent shows favorable outcomes compared to bare metal stents ... to data published online in the journal Atherosclerosis ... primary endpoint, the composite of cardiac death, myocardial infarction (MI) ... 12.4% in patients treated with a Genous Stent, a 30% ...
    Cached Medicine Technology:Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP 2OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents 2
    (Date:9/17/2014)... People who struggle to distinguish between a business ... and get the answer by reading Per Wickstrom’s latest ... that a business plan and a business strategy are both ... Wickstrom. “The way I view it is that a business ... is part two.” , According to the blog post, ...
    (Date:9/17/2014)... IL (PRWEB) September 17, 2014 The ... Pseudomonas aeruginosa infections allegedly caused by Non-Sterile Other-Sonic ... learn more about their options for legal recourse. Other-Sonic ... Drug Administration (FDA) in March 2012, after the product ... aeruginosa at William Beaumont Hospital in Royal Oak, Michigan ...
    (Date:9/17/2014)... Dennis Thompson HealthDay ... -- Exposure in the womb to household chemicals known ... developing asthma, Columbia University researchers reported in a new ... risk of developing asthma between age 5 and 11 ... levels of two phthalates (pronounced thal-ates), the researchers found. ...
    (Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
    (Date:9/17/2014)... 2014 Smart Flour Foods™ has been ... Grocer, a leading trade magazine targeted toward food retailers. ... and flavor, among other attributes. Smart Flour Foods’ Uncured ... in the September print issue of Progressive Grocer as ... pizza won based on its superior performance in the ...
    Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
    ... for the purpose of drug testing which is currently ... at the University of Manchester, well supported with a ... carcinogenic effects of new drugs are often fruitless using ... animals to establish their safety. ,Gentronix , a ...
    ... are the latest to join the fight against HIV with ... clients.// They have been recruited as part of an innovative ... the British government. This donation is expected to aid in ... by increasing testing and encouraging safer sex. ...
    ... gain at bay, says a Rhode Island researcher. Much like ... dismissed// as the fertile imagination of a maverick researcher, which ... control programmes. And while you weigh the pros and cons ... story of why the most famous ‘don’t’ of almost all ...
    ... Fresh statistics show a phenomenal rise in sexually transmitted ... of the most common treatable sexually transmitted diseases affecting ... in its incidence rates across the Australian subcontinent. with ... younger age groups with no gender distinction among the ...
    ... Haryana: This one's a very different kind of war for ... some. You bomb bacteria, not civilian populations//. And the retired ... the past 13 years. ,What began in 1993 ... and Leprosy Eradication (ABLE). Made possible through generous NRI funding ...
    ... Diligent study has helped telemedicine researchers at University of Queensland ... virtually shrinking ominous distances between cities and remote settlements in ... Eliza was created by the Centre for Online Health one ... Which is affiliated to the University of Queensland, Eliza ...
    Cached Medicine News:Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Tilt the Scales in Your Favor by Simply Weighing Yourself Everyday! 2Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2Health News:Robots Help Bring Specialist Doctors To You In A Trice 2
    ... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
    ... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
    ... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
    The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
    Medicine Products: